Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta...
Conditions: Non Hodgkin Lymphoma; Multiple Myeloma; Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma Interventions: Genetic: JCAR017; Genetic: JCARH125 Sponsor: Juno Therapeutics, Inc. Enrolling by invitation
Conclusion Haematological malignancies in the Eastern Cape Province show disparities in gender and pathology-specific incidence patterns. The present study suggest that haematological malignancies are not uncommon in this region and the incidence rate of at least one rare subtype, APL, is comparable with some European populations.
ConclusionsThe successful dexamethasone-free regimen clearly shows that dexamethasone is not a requisite component in treating multiple myeloma, and it can be substituted with clarithromycin. This regimen is particularly useful for treating patients with multiple myeloma associated with diabetes mellitus.
Prognostic factors of second allogeneic stem cell transplantation (allo-SCT2) in 78 patients with relapsed AML after first transplantation were explored. Those were poor cytogenetic risk at diagnosis, circulating blast ≥ 20% at relapse, duration from first transplant to relapse
Complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with front-line chemotherapy plus ponatinib versus earlier-generation tyrosine kinase inhibitors (TKIs) were compared in a meta-analysis and meta-regression. Patients treated with front-line ponatinib versus earlier-generation treatments were more likely to achieve CMR and had higher rates of 3-year OS.
Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow (BM), is consistently preceded by asymptomatic pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. This systematic review summarizes the currently identified clinical, imaging and genomic biomarkers, suggested to increase the progression risk or demonstrated to be differential expressed/presence between both cohorts of patients.
ConclusionsResponses to daratumumab and combinations in patients with advanced MM, particularly with extramedullary disease, are low and short lived, stressing the administration of this agent should be early in the course of the disease.This article is protected by copyright. All rights reserved.
Identifying risk factors influencing post-HSCT relapse outcome in acute leukemia is essential. 43 patients were studied. Older age and failure to achieve CR following treatment were associated with inferior OS. Female sex, extramedullary relapse and absence of post-relapse GVHD were associated with lower CR. Absence of extramedullary relapse, treatment with DLI and occurrence of post-relapse GVHD were associated with higher NRM.
Conclusion Our analysis indicates that drug approval based on phase 3 trials is more challenging for relapsed hematological malignancies than for solid malignancies. Therefore, determining proper evaluation methods for the efficacy and safety of drugs for relapsed malignancy, without randomized trials, is important.
Conditions: Multiple Myeloma; Lymphoma Intervention: Drug: 68Ga-Pentixafor Sponsor: Peking Union Medical College Hospital Not yet recruiting